8-K: Nu Skin Exceeds EPS Guidance, Narrows Revenue Outlook

Nu Skin Enterprises reported second-quarter 2025 revenue at the high end of guidance and earnings per share exceeding forecasts, driven by strong operating margin and cash position.

Summary

• Second quarter 2025 revenue was $386.1 million, at the high end of guidance, but a 12.1% decrease compared to the prior-year quarter.
• Second quarter 2025 Earnings Per Share (EPS) was $0.43, exceeding guidance, compared to $(2.38) in the prior-year quarter (or $0.21 excluding impairment and other charges).
• Operating margin improved significantly to 8.0% in Q2 2025, compared to (28.6)% in Q2 2024 (or 5.4% excluding impairment and other charges).
• Customer count decreased by 14% to 771,407, Paid Affiliates decreased by 16% to 130,799, and Sales Leaders decreased by 23% to 29,593.
• Rhyz Manufacturing segment revenue grew 17.3% year-over-year to $60.4 million.
• The company achieved a positive net cash position ahead of schedule, marking the first time in over 4 years.
• Full-year 2025 revenue guidance was narrowed to $1.48 billion to $1.55 billion, representing a 15% to 11% decline (or 11% to 7% excluding Mavely 2024 revenue).
• Full-year 2025 EPS guidance was raised to $3.05 to $3.25 (or adjusted $1.15 to $1.35).
• Third quarter 2025 revenue is projected to be $360 million to $390 million, with EPS of $0.25 to $0.35.
• The company plans a mid-Q4 2025 limited preview of its Prysm iO intelligent wellness device.
• Q4 2025 market pre-opening activities are on track for India, with a formal launch anticipated for mid-2026, leveraging 107% year-over-year revenue growth success from Latin America.

Sentiment

Score: 7

Explanation: While revenue and participant metrics declined, the company exceeded its own guidance for Q2 revenue and EPS, demonstrated strong operational efficiency with improved operating margin, achieved a positive net cash position ahead of schedule, and raised full-year EPS guidance. Strategic initiatives like the Prysm iO device and India expansion provide a clear path for future growth, despite current top-line pressures. The strong performance of Rhyz Manufacturing and Latin America also contribute positively.

Positives

• Q2 2025 EPS of $0.43 significantly exceeded the company's forecast.
• Q2 2025 revenue of $386.1 million was at the high end of guidance.
• Operating margin improved to 8.0% despite top-line pressures, reflecting successful operational optimization efforts.
• Rhyz Manufacturing segment demonstrated strong 17.3% year-over-year revenue growth.
• Achieved a positive net cash position ahead of schedule, the first time in over 4 years.
• Raised full-year 2025 EPS guidance to $3.05-$3.25 (adjusted $1.15-$1.35).
• Latin America region showed exceptional 107% year-over-year revenue growth.
• Significant progress made in building sales leader engagement and alignment for key initiatives.
• On schedule for a mid-Q4 2025 limited preview of the Prysm iO intelligent wellness device.
• On track with plans for Q4 2025 market pre-opening activities in India, with a formal launch anticipated for mid-2026.

Negatives

• Total revenue declined 12.1% year-over-year to $386.1 million in Q2 2025.
• Customer count decreased 14% to 771,407.
• Paid Affiliates decreased 16% to 130,799.
• Sales Leaders decreased 23% to 29,593.
• Significant year-over-year revenue declines in core Nu Skin segments: Mainland China (-17.7%), South Korea (-22.8%), Hong Kong/Taiwan (-18.7%), Southeast Asia/Pacific (-15.8%), Americas (-14.1%), and Europe & Africa (-8.3%).
• Gross Margin decreased to 68.8% from 70.0% year-over-year.
• Income Tax Rate increased to 23.0% from 10.2% (or 41.4% adjusted) year-over-year.
• Rhyz Other segment revenue declined 70.5%.

Risks

• Any failure of current or planned initiatives or products to generate sustained interest among the sales force and customers.
• Direct selling laws and regulations in any markets, including the United States and Mainland China, may be modified, interpreted, or enforced negatively impacting the business model, revenue, sales force, or leading to adverse actions.
• Global economic conditions and events.
• Future tax-planning initiatives, prospective or retrospective increases in duties or tariffs on products, and adverse results of tax audits or unfavorable changes to tax laws.
• Competitive pressures in the company's markets.
• Epidemics or other crises, and any related disruptions, could negatively impact the business.
• Adverse publicity related to the company's business, products, industry, or any legal actions or complaints.
• Political, legal, tax, and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets.
• Uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China.
• Risk of foreign-currency fluctuations and their currency translation impact on the business.
• Uncertainties regarding the future financial performance of acquired businesses.
• Risks related to accurately predicting, delivering, or maintaining sufficient quantities of products, and increased risk of inventory write-offs if demand is over-forecasted or strategies change.
• Regulatory risks associated with products, potentially requiring claim modification or inhibiting sales if products are determined to be medical devices or cannot be registered timely.

Future Outlook

The company projects Q3 2025 revenue between $360 million and $390 million and EPS between $0.25 and $0.35. For the full year 2025, revenue is projected to be $1.48 billion to $1.55 billion, with EPS of $3.05 to $3.25 (adjusted EPS of $1.15 to $1.35). Strategic initiatives include a mid-Q4 2025 limited preview of the Prysm iO intelligent wellness device, which is expected to stimulate growth in nutritional supplements, and Q4 2025 market pre-opening activities in India, with a formal launch anticipated for mid-2026, leveraging successful strategies from Latin America.

Management Comments

• "We are pleased with our solid performance in the second quarter including our efforts to drive revenue at the high end of our guidance and significantly exceeding our forecast for earnings per share." Ryan Napierski, President and CEO.
• "We are also pleased with our ongoing operational optimization efforts resulting in 8% operating margin despite top-line pressures on the business." Ryan Napierski, President and CEO.
• "Our Rhyz Manufacturing segment continues to perform well with 17% year-over-year revenue growth." Ryan Napierski, President and CEO.
• "We are on schedule for a mid-Q4 limited preview of our Prysm iO intelligent wellness device, the next innovation in our line of the worlds best-selling beauty and wellness device systems." Ryan Napierski, President and CEO.
• "We believe this AI-powered wellness assessment device will stimulate growth in our nutritional supplements business by providing personalized product recommendations and subscriptions to drive customer lifetime value." Ryan Napierski, President and CEO.
• "We are on track with our plans for Q4 market pre-opening activities in India with a formal launch anticipated for mid-2026." Ryan Napierski, President and CEO.
• "We remain confident in our strategy going forward to return to growth and drive shareholder value." Ryan Napierski, President and CEO.
• "We are encouraged by the positive results of our ongoing efforts to improve overall profitability, which has generated significant cash and further strengthened our balance sheet." James D. Thomas, CFO.
• "Notably, weve achieved our goal of reaching a positive net cash position ahead of schedule, marking the first time in more than 4 years that weve been in such a position." James D. Thomas, CFO.

Industry Context

Nu Skin operates in the beauty and wellness direct selling industry, which has faced challenges with declining customer and sales force engagement. The company's strategic pivot towards technology-driven wellness solutions, such as the AI-powered Prysm iO device, and personalized subscriptions aligns with broader industry trends focusing on digital engagement and recurring revenue models. The strong performance of the Rhyz Manufacturing segment indicates successful diversification into B2B services within the beauty and wellness supply chain. The expansion into India, leveraging success from Latin America, highlights a focus on emerging markets as a key growth driver amidst mature market saturation and evolving consumer behaviors.

Comparison to Industry Standards

• The company positions its upcoming Prysm iO intelligent wellness device as the "next innovation in our line of the worlds best-selling beauty and wellness device systems," based on Euromonitor International Limited research from April-May 2024, suggesting a leading market position in this specific product category.
• The 107% year-over-year revenue growth in Latin America significantly outperforms other regional segments and indicates successful market penetration strategies in developing economies, which the company aims to replicate in India.
• While specific comparable companies are not named, the direct selling industry includes major players like Herbalife, Amway, and Mary Kay, which are also navigating shifts in consumer preferences and digital transformation. Nu Skin's focus on operational optimization and new product innovation is a response to these industry-wide pressures.

Stakeholder Impact

• Shareholders: Positive impact due to exceeding EPS guidance, raised full-year EPS outlook, improved operating margin, and positive net cash position. Strategic initiatives aim to drive shareholder value.
• Employees: Potential positive impact from operational optimization efforts and strategic growth initiatives, with specific transaction bonuses noted for certain employees related to the Mavely sale.
• Customers: Introduction of new AI-powered wellness device (Prysm iO) and personalized product recommendations aims to enhance customer lifetime value and product offerings.
• Sales Force (Paid Affiliates, Sales Leaders): Decline in numbers indicates ongoing challenges, but efforts to build sales leader engagement and alignment for new initiatives are underway, which could improve future opportunities and compensation.

Next Steps

• Mid-Q4 2025: Limited preview of Prysm iO intelligent wellness device.
• Q4 2025: Market pre-opening activities in India.
• Mid-2026: Formal launch in India.
• Ongoing efforts to build sales leader engagement and alignment for key initiatives for late 2025 and 2026.

Key Dates

Recommendation

While Nu Skin exceeded its Q2 EPS and revenue guidance and improved its balance sheet by achieving a positive net cash position, the underlying business metrics show significant declines in customers, paid affiliates, and sales leaders, alongside overall revenue contraction. The strategic initiatives like Prysm iO and India expansion offer future growth potential, but their impact is yet to be realized. The raised EPS guidance is positive, but the narrowing revenue guidance still reflects ongoing top-line challenges. Given the mixed results—strong operational execution and future plans against a backdrop of declining core business metrics—a "Hold" recommendation is appropriate for investors to observe the effectiveness of the new initiatives and stabilization of the core direct selling model.

Keywords

Nu Skin, NUS, direct selling, beauty, wellness, nutritional supplements, anti-aging, personal care, Rhyz, financial results, Q2 2025, earnings, revenue, EPS, operating margin, cash position, Prysm iO, India market, global expansion, direct sales, multi-level marketing